Table 1.
Summary of the demographic and clinical data of the three sarcoidosis samples
| The Netherlands | United Kingdom | United States | Total | |
|---|---|---|---|---|
| Number | 646 | 37 | 254 | 937 |
| Age, mean ± SD | 54 ± 11 | 53 ± 10 | 55 ± 10 | 55 ± 11 |
| Male (%) | 38.2 | 18.9* | 30.0 | 35.3 |
| Time since diagnosis (%) | ||||
| < 1 year | 11.8 | 13.5 | 4.0* | 9.8 |
| 1–2 year | 12.9 | 21.6 | 10.8 | 12.7 |
| 2–5 year | 23.8* | 35.1 | 32.7 | 26.6 |
| > 5 year | 51.5 | 29.7* | 52.6 | 50.9 |
| BMI (kg/m2), mean ± SD | 28.7 ± 5.8 | 28.7 ± 6.1 | 31.5 ± 7.9* | 29.4 ± 6.5 |
| Smoker (%) | 4.5 | 11.1 | 5.3 | 5.0 |
| Non-smoker (%) | 36.8 | 47.2* | 29.9 | 35.4 |
| Former smoker (%) | 58.7 | 41.7 | 64.8 | 59.6 |
| Non-drug users (%) | 33.1 | 32.4 | 22.0* | 30 |
| Drug users (%) | ||||
| Prednisone | 40.4* | 59.5 | 52.4 | 44.4 |
| Methotrexate | 28.9 | 16.2 | 31.1 | 29.0 |
| TNF-α inhibitors | 13.2 | 2.7 | 16.5 | 13.7 |
| Azathioprine | 4.3 | 5.4 | 9.1* | 5.7 |
| Hydroxychloroquine | 9.1 | 10.8 | 17.3* | 11.4 |
| Mycophenolate mofetil | 2.0 | 0 | 6.3* | 3.1 |
| Duration of use of current drug (%) | ||||
| < 6 months | 16.2 | 16.0 | 12.5 | 15.2 |
| 6–12 months | 11.7 | 12.0 | 11.1 | 11.6 |
| > 1 year | 72.0 | 72.0 | 76.4 | 73.3 |
Data are expressed as mean ± SD or percentage if appropriate
BMI body mass index
*Value differs significantly from the two other countries (p < 0.05)